A detailed history of Adar1 Capital Management, LLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Adar1 Capital Management, LLC holds 251,400 shares of TSHA stock, worth $517,884. This represents 0.08% of its overall portfolio holdings.

Number of Shares
251,400
Previous 250,800 0.24%
Holding current value
$517,884
Previous $562 Million 10.05%
% of portfolio
0.08%
Previous 0.11%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.01 - $2.46 $1,205 - $1,476
600 Added 0.24%
251,400 $505 Million
Q2 2024

Aug 13, 2024

BUY
$2.04 - $4.17 $422,892 - $864,441
207,300 Added 476.55%
250,800 $562 Million
Q1 2024

May 15, 2024

SELL
$1.43 - $3.25 $236,665 - $537,875
-165,500 Reduced 79.19%
43,500 $125 Million
Q4 2023

Feb 14, 2024

BUY
$1.33 - $2.88 $277,970 - $601,920
209,000 New
209,000 $370 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $99.6M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.